Minnesota is currently home to 2063 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Blood Biomarkers in Pediatric Kidney Transplant Recipients
NCT05477082
Recruiting
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody mediated rejection. The study hypothesizes that blood gene expression profile and donor-derived cell-free DNA biomarkers (omnigraf) can be used to predict acute rejection and monitor its response to treatment.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/29/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Rejection of Kidney Allograft
Register for Updates
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Minnesota Oncology Hematology, Minneapolis, Minnesota
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
Neuroplasticity in RBD
NCT05471960
Recruiting
REM sleep behavior disorder is a parasomnia that reflects the presence of alpha-synucleinopathy in the brain and is highly predictive of eventual phenoconversion to Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy over the course of years to decades. Neuroplastic adaptations in the brain during the prodromal stage of disease are thought to mask the expression of motor and non-motor signs and may substantially delay diagnosis during a potentially critical time window. Th... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
08/27/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: REM Sleep Behavior Disorder
Register for Updates
Safety and Tolerability of Pirfenidone in Acute Pancreatitis
NCT05350371
Recruiting
The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is currently approved by FDA for the treatment of idiopathic pulmonary fibrosis. Now, over 5 years of data has accumulated demonstrating safety of its use in humans. The investigators' preclinical data suggest that pirfenidone is very effective in reducing the severity of acute pancreatitis in animal models.... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pancreatitis, Acute
Register for Updates
Distal Radius Interventions for Fracture Treatment
NCT05131685
Recruiting
This protocol describes a multicenter, prospective randomized superiority trial comparing functional outcomes between children treated with sedated reduction versus no formal reduction.
Gender:
ALL
Ages:
Between 4 years and 10 years
Trial Updated:
08/27/2024
Locations: Gillette Children's Specialty Healthcare, Saint Paul, Minnesota
Conditions: Fracture Distal Radius
Register for Updates
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Register for Updates
Neuromodulation and Cognitive Training for Substance Use Disorders
NCT04426214
Recruiting
The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. This study is testing a new intervention, namely tDCS-Augmented Cognitive Training, to engage these brain biomarkers to improve cognition and improve t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/27/2024
Locations: University of Minnesota Fairview, Minneapolis, Minnesota
Conditions: Stimulant Use, Alcohol Use Disorder
Register for Updates
From Opinion to Evidence: Multi-site Evaluation of Custom Dynamic Orthosis Best Practices
NCT06352788
Recruiting
This study is designed to support evidence-based practice and optimal care by evaluating how different configurations of two types of carbon fiber custom dynamic orthoses (CDOs) influences outcomes following traumatic lower extremity injury.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/26/2024
Locations: Minneapolis VA Health Care System - Motion Analysis Laboratory, Minneapolis, Minnesota
Conditions: Foot Injury
Register for Updates
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
NCT06323824
Recruiting
The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/26/2024
Locations: Hennepin Healthcare Addiction Medicine, Minneapolis, Minnesota
Conditions: Opioid Use Disorder
Register for Updates
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
NCT06106295
Recruiting
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Register for Updates
Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients
NCT06015932
Recruiting
This clinical trial tests how well cognitive behavioral cancer stress management (CBCSM) group sessions work to decrease psychological distress in cancer patients. CBCSM teaches patients how to recognize and reduce the impacts of cancer associated stress on the biological, psychological, and social life domains.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Register for Updates
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200
Recruiting
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: GSK Investigational Site, Minneapolis, Minnesota
Conditions: Colonic Neoplasms, Neoplasms, Colon
Register for Updates